MedEx answers any queries you might have regarding Prograf-5 purchase, shipping and payment terms.
Feel free to contact support through inquiry form, MedeEx is fully dedicated towards your needs 24/7.
Prograf 5mg capsules are made of Tacrolimus and auxiliary components.
Thanks to the active component of Tacrolimus, Prograf 5mg has a pronounced immunosuppressive effect. The drug accumulates inside the cells by binding to FKBP12. Further action of the drug continues by binding to calcineurin and inhibition of it. Thus, Prograf prevents transcription of the disk group of lymphokine genes, which leads to inhibition of lymphocyte production and decrease in T-cell activity.
The effect of the drug helps to resist rejection of transplants.
Indications for use
It is used to prevent rejection of transplanted organs by the body, after transplantological operations. Prograf 5mg should be used after transplantation of heart, kidney, liver and other organs and tissues.
Method of application
The dose of the drug depends on the individual patient data.
The capsules are recommended to take on an empty stomach, having drunk a large amount of water. The reception is divided into 2 times.
The infusion solution is injected after dilution with dextrose or saline (only in transparent colorless bottles and liquids).
If an adult has experienced liver transplantation, they are prescribed an immunosuppression therapy with capsules of 0.1-0.2 mg per 1 kg per day, or a solution of 0.01-0.05 mg/kg / day (the duration of infusion is 24 hours). The therapy can start within 12 hours after surgical manipulation.
If a child has experienced liver of heart transplantation (regardless of age), they should be prescribed an immunosuppression therapy with capsules of 0.3 mg per 1 kg per day, or a solution of 0.05 mg/kg/day ( the duration of infusion 24 hours). The therapy can start within 12 hours after surgical manipulation.
People with severe liver disease should take Prograf at a minimum level.
Patients with severe renal disease need constant monitoring of kidneys (creatine level, creatine clearance, diuresis).
Maintenance therapy (regardless of age) implies the reduction of the initial dosage of Prograf. In some cases, there is also the abolition of concomitant therapy with immunosuppressants.
The dosage of Prograf for children is on average 1.5-2 times higher than for adults.
Treatment for rejection is carried out with high doses in combination with corticosteroids and mono/polyclonal antibodies.
Treatment with Prograf is almost always accompanied by hypertension, insomnia, diarrhea, vomiting or nausea, impaired renal function, increased glucose and potassium in blood, diabetes, headache, tremor and pain of a certain location (joints, muscles, etc.).